Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

2.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

698
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
Anthelminthic Agents01:15

Anthelminthic Agents

52
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
52
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

764
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
764

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiota Therapy: Ready for Clinical Practice?

Visceral medicine·2024
Same author

Childlessness in Patients with Inflammatory Bowel Disease - Data from the Prospective Multi-center Swiss IBD Cohort Study.

Journal of gastrointestinal and liver diseases : JGLD·2023
Same author

Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.

Journal of Crohn's & colitis·2023
Same author

Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines.

Annals of gastroenterology·2023
Same author

[Microbiome: from pathophysiology to clinical application?]

Deutsche medizinische Wochenschrift (1946)·2023
Same author

Crosstalk within peripheral blood mononuclear cells mediates anti-inflammatory effects of n-3 PUFA-rich lipid emulsions in parenteral nutrition.

Clinical nutrition (Edinburgh, Scotland)·2023

Related Experiment Video

Updated: Apr 6, 2026

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
12:40

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products

Published on: April 6, 2015

19.7K

Helminth therapy for organic diseases?

Irina Leonardi1, Isabelle Frey1, Gerhard Rogler2

  • 1Division of Gastroenterology and Hepatology, University Hospital Zürich, Zurich, Switzerland.

Translational Research : the Journal of Laboratory and Clinical Medicine
|July 25, 2015
PubMed
Summary

Increased autoimmune diseases may stem from reduced helminth parasite exposure. This review examines helminth therapies, exploring translational studies and solutions for optimizing their use in treating inflammatory conditions.

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K

Related Experiment Videos

Last Updated: Apr 6, 2026

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
12:40

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products

Published on: April 6, 2015

19.7K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K

Area of Science:

  • Immunology
  • Epidemiology
  • Parasitology

Background:

  • Autoimmune and chronic inflammatory diseases are rising globally, termed "postindustrial revolution epidemics."
  • Increased hygiene standards may have reduced exposure to coevolved helminth parasites essential for immune system regulation.
  • Helminth-based therapies are being investigated as a potential treatment for these conditions.

Purpose of the Study:

  • To review translational and clinical studies on helminth therapies.
  • To identify challenges and propose solutions for optimizing helminth-based treatments.
  • To explore the role of helminths in immune system functioning and disease modulation.

Main Methods:

  • Comprehensive literature review of translational and clinical studies.
  • Analysis of existing research on helminth-host immune interactions.
  • Synthesis of data on the efficacy and safety of various helminth therapies.

Main Results:

  • Several helminth species have been investigated for therapeutic potential.
  • Translational and clinical data highlight both promise and challenges in helminth therapy development.
  • Optimization strategies are crucial for successful clinical application.

Conclusions:

  • Helminth therapy holds potential for managing autoimmune and inflammatory diseases.
  • Further research and optimized protocols are needed to overcome current limitations.
  • Restoring helminth-host interactions may offer a novel approach to immune system regulation.